T Du1, J Zhang1, G Yuan1, M Zhang1, X Zhou1, Z Liu1, X Sun2, X Yu3. 1. Department of Endocrinology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China. 2. Department of Anesthesiology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China. Electronic address: sunxx1984@gmail.com. 3. Department of Endocrinology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China. Electronic address: xuefengyu188@gmail.com.
Abstract
BACKGROUND AND AIMS: Increased cardiovascular disease and mortality risk in metabolically healthy obese (MHO) individuals remain highly controversial. Several studies suggested risk while others do not. The traditional cardiovascular risk factors may be insufficient to demonstrate the complete range of metabolic abnormalities in MHO individuals. Hence, we aimed to compare the prevalence of elevated lipoprotein (a), apolipoprotein B, and uric acid (UA) levels, apolipoprotein B/apolipoprotein A1 ratio, and visceral adiposity index (VAI) scores, and low apolipoprotein A1 levels among 6 body size phenotypes (normal weight with and without metabolic abnormalities, overweight with and without metabolic abnormalities, and obese with or without metabolic abnormalities). METHODS AND RESULTS: We conducted a cross-sectional analysis of 7765 Chinese adults using data from the nationwide China Health and Nutrition Survey 2009. MHO persons had intermediate prevalence of elevated apolipoprotein B and UA levels, apolipoprotein B/apolipoprotein A1 ratio and VAI scores, and low apolipoprotein A1 levels between metabolically healthy normal-weight (MHNW) and metabolically abnormal obese individuals (P < 0.001 for all comparisons). Elevated apolipoprotein B and UA concentrations, apolipoprotein B/apolipoprotein A1 ratio, and VAI scores were all strongly associated with the MHO phenotype (all P < 0.01). CONCLUSIONS: Prevalence of elevated apolipoprotein B and UA levels, apolipoprotein B/apolipoprotein A1 ratio and VAI scores, and low levels of apolipoprotein A1 was higher among MHO persons than among MHNW individuals. The elevated levels of the nontraditional risk factors and VAI scores in MHO persons could contribute to the increased cardiovascular disease risk observed in long-term studies.
BACKGROUND AND AIMS: Increased cardiovascular disease and mortality risk in metabolically healthy obese (MHO) individuals remain highly controversial. Several studies suggested risk while others do not. The traditional cardiovascular risk factors may be insufficient to demonstrate the complete range of metabolic abnormalities in MHO individuals. Hence, we aimed to compare the prevalence of elevated lipoprotein (a), apolipoprotein B, and uric acid (UA) levels, apolipoprotein B/apolipoprotein A1 ratio, and visceral adiposity index (VAI) scores, and low apolipoprotein A1 levels among 6 body size phenotypes (normal weight with and without metabolic abnormalities, overweight with and without metabolic abnormalities, and obese with or without metabolic abnormalities). METHODS AND RESULTS: We conducted a cross-sectional analysis of 7765 Chinese adults using data from the nationwide China Health and Nutrition Survey 2009. MHO persons had intermediate prevalence of elevated apolipoprotein B and UA levels, apolipoprotein B/apolipoprotein A1 ratio and VAI scores, and low apolipoprotein A1 levels between metabolically healthy normal-weight (MHNW) and metabolically abnormal obese individuals (P < 0.001 for all comparisons). Elevated apolipoprotein B and UA concentrations, apolipoprotein B/apolipoprotein A1 ratio, and VAI scores were all strongly associated with the MHO phenotype (all P < 0.01). CONCLUSIONS: Prevalence of elevated apolipoprotein B and UA levels, apolipoprotein B/apolipoprotein A1 ratio and VAI scores, and low levels of apolipoprotein A1 was higher among MHO persons than among MHNW individuals. The elevated levels of the nontraditional risk factors and VAI scores in MHO persons could contribute to the increased cardiovascular disease risk observed in long-term studies.
Authors: Rachel P Wildman; Robert Kaplan; JoAnn E Manson; Aleksandar Rajkovic; Stephanie A Connelly; Rachel H Mackey; Lesley F Tinker; J David Curb; Charles B Eaton; Sylvia Wassertheil-Smoller Journal: Obesity (Silver Spring) Date: 2011-01-13 Impact factor: 5.002
Authors: Kevin E Kip; Oscar C Marroquin; David E Kelley; B Delia Johnson; Sheryl F Kelsey; Leslee J Shaw; William J Rogers; Steven E Reis Journal: Circulation Date: 2004-02-17 Impact factor: 29.690
Authors: Leo K Niskanen; David E Laaksonen; Kristiina Nyyssönen; Georg Alfthan; Hanna-Maaria Lakka; Timo A Lakka; Jukka T Salonen Journal: Arch Intern Med Date: 2004-07-26
Authors: Esther C Gallegos-Cabriales; Ernesto Rodriguez-Ayala; Hugo A Laviada-Molina; Edna J Nava-Gonzalez; Rocío A Salinas-Osornio; Lorena Orozco; Irene Leal-Berumen; Juan Carlos Castillo-Pineda; Laura Gonzalez-Lopez; Claudia Escudero-Lourdes; Judith Cornejo-Barrera; Fabiola Escalante-Araiza; Eira E Huerta-Avila; Fatima A Buenfil-Rello; Vanessa-Giselle Peschard; Eliud Silva; Rosa A Veloz-Garza; Angelica Martinez-Hernandez; Francisco M Barajas-Olmos; Fernanda Molina-Segui; Lucia Gonzalez-Ramirez; Ruy D Arjona-Villicaña; Victor M Hernandez-Escalante; Janeth F Gaytan-Saucedo; Zoila Vaquera; Monica Acebo-Martinez; Areli Murillo-Ramirez; Sara P Diaz-Tena; Benigno Figueroa-Nuñez; Melesio E Valencia-Rendon; Rafael Garzon-Zamora; Juan Manuel Viveros-Paredes; Salvador B Valdovinos-Chavez; Anthony G Comuzzie; Karin Haack; Ashley A Thorsell; Xianlin Han; Shelley A Cole; Raul A Bastarrachea Journal: Biology (Basel) Date: 2021-12-16